KPTIQ Karyopharm Therapeutics Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%
Returns
ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x
Leverage & solvency
Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $146.07M | $145.24M | $146.03M | $157.07M | $20.00M |
| R&D expense | $125.62M | $143.23M | $138.75M | $148.66M | $160.84M |
| SG&A expense | $105.21M | $115.44M | $131.88M | $145.40M | $143.85M |
| Operating income | -$90.71M | -$119.44M | -$129.54M | -$142.20M | -$98.27M |
| Interest expense | $45.85M | $37.42M | $23.82M | $25.00M | $26.05M |
| Pretax income | -$196.00M | -$76.36M | -$142.78M | -$164.92M | -$123.82M |
| Income tax | $43,000 | $57,000 | $323,000 | $369,000 | $268,000 |
| Net income | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -$124.09M |
| EBITDA | -$90.41M | -$119.10M | -$129.01M | -$141.58M | -$97.48M |
| EPS (basic) | -17.93 | -9.41 | -18.79 | -2.02 | -1.65 |
| EPS (diluted) | -17.93 | -14.00 | -18.79 | -2.02 | -1.65 |
| Weighted avg. shares (diluted) | 10,935 | 8,455 | 7,616 | 81,871 | 75.22M |
| Balance sheet | |||||
| Cash & equivalents | $60.54M | $62.81M | $52.23M | $136.88M | $197.44M |
| Short-term investments | $3.20M | $46.24M | $139.21M | $142.78M | $38.16M |
| Receivables | $26.18M | $30.77M | $26.96M | $47.09M | $22.50M |
| Inventory | $4.04M | $4.74M | $3.04M | $4.22M | $4.11M |
| Current assets | $103.15M | $156.46M | $233.92M | $350.16M | $275.61M |
| PP&E, net | $104,000 | $400,000 | $606,000 | $1.14M | $1.64M |
| Total assets | $108.42M | $164.42M | $240.44M | $358.17M | $305.31M |
| Current liabilities | $92.06M | $92.26M | $69.48M | $65.91M | $73.72M |
| Long-term debt | — | — | — | — | $169.29M |
| Total debt | — | — | — | — | $169.29M |
| Total liabilities | $401.34M | $350.44M | $376.64M | $374.83M | $384.98M |
| Shareholders' equity | -$292.93M | -$186.02M | -$136.21M | -$16.66M | -$79.67M |
| Net debt | — | — | — | — | -$28.15M |
| Shares outstanding | 18.31M | 8.41M | 114.92M | 113.21M | 75.75M |
| Cash flow statement | |||||
| Operating cash flow | -$75.37M | -$127.49M | -$92.72M | -$149.55M | -$107.12M |
| Capital expenditure | $0 | $142,000 | $0 | $118,000 | $212,000 |
| Free cash flow | -$75.37M | -$127.63M | -$92.72M | -$149.67M | -$107.33M |
| Investing cash flow | $43.38M | $95.47M | $7.94M | -$104.26M | $141.84M |
| Financing cash flow | $30.05M | $41.65M | $1.12M | $193.74M | $73.65M |
| Depreciation & amortization | $296,000 | $340,000 | $530,000 | $621,000 | $789,000 |
| Stock-based compensation | $14.05M | $18.43M | $21.71M | $35.40M | $29.78M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.